NEW YORK (GenomeWeb News) – The University of Manchester's Institute of Cancer Sciences said today that it will lead an international consortium that will use €6 million ($7.9 million) in funding to develop genetic biomarkers to identify patients who are at risk of developing long-term side effects from radiation therapy.

The 13 members involved in the EU-funded project, called REQUITE, plan to develop these markers specifically for patients with breast, prostate, and lung cancer who receive radiation therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.